Nipro Renal Soultions USA, Corporation — Class II: MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and BC+201
Nipro Renal Solutions USA has initiated a Class II recall for MedicaLyte Liquid Bicarbonate Concentrate (REF: BC-100 and BC+201) due to high endotoxin levels. The recall is currently classified as ongoing.
This affects Nipro Renal Solutions USA, healthcare facilities utilizing MedicaLyte Liquid Bicarbonate Concentrate, and professionals in quality assurance, clinical dialysis, and medical device manufacturing.
High endotoxin levels in hemodialysis concentrates present a significant clinical risk, potentially leading to pyrogenic reactions or systemic inflammatory responses in patients. From a regulatory perspective, this indicates a potential failure in the manufacturing process or contamination control strategies, necessitating a review of environmental monitoring and batch release criteria for liquid concentrates.
QA teams should verify current inventory against the specified REF numbers and evaluate existing endotoxin testing protocols for liquid concentrates. Regulatory and clinical teams should monitor the ongoing status of this recall to ensure all affected lots are identified and managed according to the firm's remediation plan.
Class II. Reason: Hemodialysis concentrates contain high endotoxin levels. Product: MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and BC+201. Firm: Nipro Renal Soultions USA, Corporation (Lewisberry PA United States). Status: Ongoing.
Open in openFDA / FDA.gov